A Chinese cancer drug developer is pushing ahead with an initial public offering in Hong Kong, despite a global markets rout and the recent poor performance of other biotechnology startups that have listed in the city.
from WSJ.com: US Business https://ift.tt/2Ey7gkr
via IFTTT
No comments:
Post a Comment